BD, a global medical technology company based in Franklin Lakes, will have about $16 billion in annualized revenue after the transaction. Medical device-maker Bard, based in Murray Hill, will become a wholly owned subsidiary of BD, with each share of Bard common stock converted to either $222.93 in cash or 0.5077 of a share of BD common stock.
At the time the deal was announced in April, it was valued at approximately $24 billion.
“Today is a historic day for BD, as welcome Bard and its 16,000 associates to BD,” Chairman and CEO Vincent A. Forlenza said in a prepared statement. “These companies each have a legacy of more than 100 years of advancing the world of health and supporting those on the front lines of health care. We look forward to continuing to lead the industry through innovation and partnerships that bring more valuable solutions to our customers and their patients.”